Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anagliptin vs Linagliptin in T2DM Combination Therapy
NCT07442006Phase 4Recruiting
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of anagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoint: Mean Amplitude of Glycemic Excursion at 12 weeks. Started Oct 2025; status: recruiting.
02
Drugs
anagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07442006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07442006.